135 related articles for article (PubMed ID: 37246571)
1. 2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.
Anghelone A; Strusi A; Scala A; Panebianco M; Ciccarese C; Iacovelli R
Expert Rev Anticancer Ther; 2023 Jul; 23(7):669-672. PubMed ID: 37246571
[TBL] [Abstract][Full Text] [Related]
2. 2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.
Iacovelli R; Cannella MA; Ciccarese C; Astore S; Foschi N; Palermo G; Tortora G
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1203-1206. PubMed ID: 34482771
[TBL] [Abstract][Full Text] [Related]
3. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
5. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
8. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
[TBL] [Abstract][Full Text] [Related]
10. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
14. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
[TBL] [Abstract][Full Text] [Related]
16. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
17. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
Beypınar I; Sözel Y; Önder AH
Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
[TBL] [Abstract][Full Text] [Related]
18. IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Panunzio A; Tappero S; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Antonelli A; Kosiba M; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
Semin Oncol; 2022 Oct; 49(5):394-399. PubMed ID: 36333148
[TBL] [Abstract][Full Text] [Related]
19. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.
Borchiellini D; Maillet D
Bull Cancer; 2022 May; 109(2S):2S4-2S18. PubMed ID: 35760470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
